The company is taking the step to continue listing its shares on the Nasdaq, which had warned OpGen that did not meet a listing requirement calling for a minimum bid price of $1 per share.
Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.
The company's stock faced delisting for trading below $1 for 30 consecutive business days in violation of the Nasdaq's requirements.
OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.
Last month, the company was notified that it no longer met the Nasdaq's stockholder equity listing requirement and faced delisting.
Earlier this year, Rosetta effected a 1-for-12 reverse stock split after failing to meet the Nasdaq's $1 minimum bid price requirement.
The molecular diagnostics firm was told on Wednesday that it is again in compliance with a rule calling for a $1 minimum bid on its share price.
The firm's market value fell below the minimum $35 million level to remain listed on the Nasdaq. HTG has until Jan 29, 2018 to regain compliance.
Nasdaq told the firm on Tuesday that its shares failed to maintain a minimum bid price of $1 per share for at least 30 consecutive trading days.
The firm said today that it received a notice that it is out of compliance with a rule requiring timely filings with the US Securities and Exchange Commission.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.